Chemical ionization mass spectrometry, using isobutane as a reactant gas, is shown to be useful in the structural characterization of representative 16-membered ring macrolide antibiotics.
(Received for publication November 6, 1972) Chemical ionization mass spectrometry, using isobutane as a reactant gas, is shown to be useful in the structural characterization of representative 16-membered ring macrolide antibiotics.
The spectra of spiramycin I, spiramycin III, and niddamycin contain relatively intense protonated molecule ion peaks (MH+) making establishment of molecular formulae straightforward. There are relatively few fragment ion peaks in comparison with the corresponding electron impact mass spectra, but these peaks are nonetheless highly significant.
The major fragmentations observed involve sequential loss of the sugar moieties and loss of other small molecules such as water, acetic acid, and methanol.
Scission of carbon-carbon bonds is uncommon. The nature of these reactions and the mechanisms responsible are discussed briefly. 
Materials and Methods
Spiramycins I and III8) were obtained from Dr. T. Nara of the Kyowa Hakko Kogyo Company, and niddamycin9) was obtained from Mr. L. Theriault of Abbott Laboratories (U.S.A.).
The mass spectra were obtained using an AEI MS-9mass spectrometer equipped with a SRIC CIS-2 chemical ionization source. The isobutane pressure within the ion block was The mass spectra were recorded both on magnetic tape with subsequent computerprocessing, and on an oscillographic recorder.
Results and Discussion A variety of reactant gases have been used in GI-MS; however, we find that isobutane offers signficant advantages. Electron bombardment of the isobutane results in formation of a relatively stable, proton-rich and sterically hindered carbonium ion (G4H9+) which readily transfers protons to atoms bearing nonbonded electron pairs.10)
The resulting protonated molecule ions (MH+) are relatively stable, resulting in intense peaks in the GI-MS. The fragmentations which do occur most frequntly involve heterolysis of carbon-oxygen bonds by mechanisms which closely parallel those encountered in proton reactions in solution.n) These considerations are best illustrated by examining the spectra of several examples.
The GI-MS of spiramycin I8) {Fig. 1) shows an intense protonated molecule ion peak at mje 843. The à"small peak at m\e 899 results from .attachment of a £-butyl carbonium ion to the spiramycin molecule. Adduct ions of this type are normal in CI-MS, consequently, they do not The actual mechanism involved in the formation of these ions is being investigated ; however, it appears to involve protonation at a heteroatom followed by a four-centered fragmentation of a glycosidic bond such as illustrated in Reaction (1). Additional evidence regarding the structures of the sugars is provided by prominent sugar fragment ions in the low-mass region of the specrum. The mje 142 ion is the base peak and probably results from protonation of the anomeric oxygen of the sugar followed by bond cleavage (Reaction 2). The same process involving the other terminal sugar is the probable source of the m/e 145ion, which readily loses amolecule of water to give the m/e 127ion. The ion at m\e 336 corresponds to the protonated disaccharide and conveniently provides sugar-sequencing information.
Unlike EI-MS, doubly charged ions do not appear in isobutane GI-MS. If double protonation could occur, one would expect to see evidence for it in the CI-MS of the spiramycins since they have two basic centers (Me2N-) relatively remote from each other. Even at high amplification no peak was detected at m\e 422.5 corresponding to the 13C-isotope peak of MH2++.
Spiramycin III differs from spiramycin I in having a propionyl ester /? to the lactone carbonyl rather than a hydroxyl group. This kind of substituent difference is commonamong the 16-membered ring macrolides ; for example, the leucomycins and maridomycins. Under the isobutane CI-MS conditions fragmentation involving loss of propionic acid competes effectively with loss of the terminal sugars. Consequently, the GI-MS (Fig. 2) 
